Literature DB >> 19088500

Downmodulatory effects of the antihistaminic drug bepotastine on cytokine/chemokine production and CD54 expression in human keratinocytes.

M Kobayashi1, K Kabashima, M Nakamura, Y Tokura.   

Abstract

Bepotastine besilate is an antihistaminic drug of the second generation with superior clinical responses. In this study, we investigated whether bepotastine modulates the production of cytokines/chemokines and the expression of CD54 in human epidermal keratinocytes. The production of IL-1alpha, CXCL10, and CCL17 and the expression of CD54 were significantly suppressed by the addition of bepotastine. Bepotastine exerts its antiallergic action on keratinocytes by suppressing the production of certain proinflammatory cytokines, both Th1 and Th2 chemokines, and possibly by inhibiting the expression of CD54. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19088500     DOI: 10.1159/000183924

Source DB:  PubMed          Journal:  Skin Pharmacol Physiol        ISSN: 1660-5527            Impact factor:   3.479


  4 in total

Review 1.  Oral bepotastine: in allergic disorders.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

2.  Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function.

Authors:  Tzu-Kai Lin; Mao-Qiang Man; Juan-Luis Santiago; Kyungho Park; Truus Roelandt; Yuko Oda; Melanie Hupe; Debra Crumrine; Hae-Jin Lee; Maria Gschwandtner; Jacob P Thyssen; Carles Trullas; Erwin Tschachler; Kenneth R Feingold; Peter M Elias
Journal:  J Invest Dermatol       Date:  2012-09-27       Impact factor: 8.551

3.  Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis.

Authors:  Jeremy B Wingard; Francis S Mah
Journal:  Clin Ophthalmol       Date:  2011-02-15

4.  An Investigator-Blind Randomized Controlled Trial Comparing Effectiveness, Safety of Levocetirizine and Bepotastine in Chronic Urticaria.

Authors:  Amrita Sil; Sufiur Rahaman; Nasiruddin Mondal; Sk Shahriar Ahmed; Dhiman Tarafdar; Aparesh Chandra Patra; Sudipta Roy; Nilay Kanti Das
Journal:  Indian J Dermatol       Date:  2021 Sep-Oct       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.